Evidence map›Paper›PMID 35499211›Full record

ArticleJournal of viral hepatitis2022

Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015-2018.

Katie Healy, Urban Freij, Marie Ellerstad, Linda B S Aulin, Lena Brückle, Helen Hillmering, Margaret Sällberg Chen, Rasmus Gustafsson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Increasing trends in hepatitis E hospitalisations in Spain, 1997 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  3. Article
  4. Hepatitis E virus infections in German blood donors: results of 8 years of screening, 2015 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Transmission of Hepatitis E Virus.Advances in experimental medicine and biology · 2023
    Article
  9. Development and characterization of secondary standards for nucleic acid amplification technology (NAAT) assays for detection of hepatitis E virus.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 5 countries.

Katie HealyDivision of Clinical Diagnostics and Surgery, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Urban FreijOctapharma AB, Stockholm, Sweden.
Marie EllerstadOctapharma AB, Stockholm, Sweden.
Linda B S AulinLeiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Lena BrückleOctapharma Plasma GmbH, Langenfeld, Germany.
Helen HillmeringOctapharma AB, Stockholm, Sweden.
Margaret Sällberg ChenDivision of Clinical Diagnostics and Surgery, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Rasmus GustafssonOctapharma AB, Stockholm, Sweden.ORCID 0000-0002-0876-9573
Karolinska Institutet · SEOctapharma (United States) · USLeiden University · NLOctapharma (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is endemic in Europe. However, standardized methods for the surveillance of HEV viremia in the general population are lacking. This study aimed to compare the incidence of HEV among blood donors in two European countries, Germany and Portugal, during the period 2015-2018. The seasonal distribution of HEV infection, as well as host risk factors including age, sex, and blood group phenotype were explored. A total of 191,236 donations from Germany and Portugal were tested for HEV RNA in plasma mini-pools of up to 96 donations using an internally controlled reverse transcription real-time PCR (RT-PCR) assay. The 95% cut-off of the assay was 15 International Units (IU)/mL (CI 10-35 IU/mL) as determined by dilution of the WHO International Standard for HEV RNA. Blood type was determined by agglutination and pattern recognition using the Beckmann Coulter PK 7300 AB0- and Rhesus-Assay. The overall positivity rate was 0.09% with significantly more infections observed in the German cohort (p < 0.0001). Infections peaked in the summer months, and investigation of risk factors revealed that incidence was significantly higher amongst males (p = 0.0002), but was not associated with ABO or Rh(D) blood group phenotypes. No significant relationships between risk factors and viral load were observed. Our findings confirm that HEV infections are highly prevalent in Europe, even amongst otherwise healthy blood donors. Increasing awareness of the seasonal spread and risk factors for HEV transmission is of great importance for individuals susceptible to more severe forms of the disease, such as immunocompromised patients.

Indexed as

Blood Group AntigensHepatitis EHepatitis E virusBlood DonorsHepatitis AntibodiesHumansMalePrevalenceRNARNA, ViralBlood Group AntigensHepatitis AntibodiesRNARNA, ViralABOhepatitis E virusrhesusRT-PCRtransfusion medicineviremia

Identifiers

PMID35499211
PMCPMC9545359
OpenAlexW4225263217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.